DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
ORE-1001 is an investigational drug.
There have been 8 clinical trials for ORE-1001. The most recent clinical trial was a Phase 3 trial, which was initiated on August 25th 2017.
The most common disease conditions in clinical trials are Osteoarthritis, Knee, Osteoarthritis, and Cardiovascular Diseases. The leading clinical trial sponsors are IRCCS Policlinico S. Matteo, Azienda Ospedaliera Spedali Civili di Brescia, and Tehran University of Medical Sciences.
There are three US patents protecting this investigational drug and twenty-five international patents.
Recent Clinical Trials for ORE-1001
|Parabens Flocculation on the Anti Inflammatory Effects of Corticosteroid Injections for Total Knee Arthroplasty||Loma Linda University||Early Phase 1|
|Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines||San Luigi Gonzaga Hospital||Phase 2|
|Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines||Azienda Ospedaliera Spedali Civili di Brescia||Phase 2|
Top disease conditions for ORE-1001
Top clinical trial sponsors for ORE-1001
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|ORE-1001||See Pricing||ACE-2 modulating compounds and methods of use thereof||Millennium Pharmaceuticals, Inc. (Cambridge, MA)||See Pricing|
|ORE-1001||See Pricing||Method for treating inflammatory diseases of the digestive tract||Ore Pharmaceuticals Inc. (Cambridge, MA)||See Pricing|
|ORE-1001||See Pricing||Peptide-peptidase-inhibitor conjugates and methods of making and using same||Amylin Pharmaceuticals, LLC (San Diego, CA) AstraZeneca Pharmaceuticals LP (Wilmington, DE)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|